A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC)
- 31 March 2006
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 51 (3) , 357-362
- https://doi.org/10.1016/j.lungcan.2005.10.023
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert PanelJournal of Clinical Oncology, 2005
- Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)Journal of Clinical Oncology, 2005
- The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxelCancer, 2003
- Participation of Patients 65 Years of Age or Older in Cancer Clinical TrialsJournal of Clinical Oncology, 2003
- Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized TrialJNCI Journal of the National Cancer Institute, 2003
- Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized TrialJNCI Journal of the National Cancer Institute, 2002
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scaleCancer, 1994
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976